Chemistry, Probes & Molecular Therapy (CPMT): "Opportunities and Directions in Cancer Metabolism Research Enabled by Quantitative Imaging"

H. Charles Manning is a chemist with a background in radiochemistry, medicinal chemistry and imaging science. Since starting his independent career at Vanderbilt University in 2006, his laboratory has focused on the discovery, translation, and validation of chemical and molecular probes for cancer imaging and therapy. During his tenure at Vanderbilt, Dr. Manning rose to the academic rank of Professor of Radiology, Chemistry, Biomedical Engineering, Neurosurgery, and Chemical and Physical Biology. As a Vanderbilt Ingram Professor of Cancer Research, Dr. Manning served the Ingram Cancer Center as the Director of Cancer Imaging Research starting in 2015. Dr. Manning also served as the founding Director of the Vanderbilt Center for Molecular Probes and Molecular Imaging Research. In this role, he led the scientific direction of Vanderbilt’s radiopharmaceutical and molecular imaging research programs. Continuously supported by the National Cancer Institute (NCI) throughout his career, as well as the DOD, industry and philanthropy partners, Dr. Manning’s lab discovers and translates novel radiopharmaceuticals and chemical probes, with emphasis on positron emission tomography (PET) imaging.

 

 In 2020, the Manning Laboratory relocated to MD Anderson Cancer Center in Houston, Texas. At MD Anderson, Dr. Manning is a Professor in the Department of Cancer Systems Imaging and serves as the Scientific Director of the Center for Advanced Biomedical Imaging (CABI) in the Division of Diagnostic Imaging. He is a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar. The current directions of the Manning lab focus on quantifying cellular metabolism non-invasively through the use of high-affinity ligands for receptor-based targets and metabolic substrate transporters elevated in cancer cells.